What changed in this filing

/stocks — the workspaceLOADING

Item 9A. Controls and Procedures

2026-02-24 compared with 2025-02-28 · 52 added, 75 removed, 174 unchanged (42% of the section changed)

45 unchanged sentences

Rule 10b5-1 Trading Plans

On December 12, 2024 , Dale Muzzey , the Company's Chief Scientific Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

The plan provides for the sale of up to 22,906 shares of common stock.

The plan expires on the earlier of (i) the date all of the shares under the plan have been sold and (ii) December 31, 2025 .

Except as disclosed above, none of our directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as such term is defined in Item 408(a) of Regulation S-K.

On November 19, 2025 , Rashmi Kumar , a member of our Board of Directors , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

The plan provides for the sale of up to 15,000 shares of our common stock.

The plan expires on the earlier of (i) the date all of the shares under the plan have been sold and (ii) September 30, 2026 .

Except as disclosed above, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K).

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

1 unchanged sentence

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The response to this item is incorporated by reference from the discussion responsive thereto under the captions “Management and Corporate Governance,” “Corporate Code of Conduct” and “ Insider Trading Policies” in our Proxy Statement for the 2025 Annual Meeting of Stockholders expected to be held on June 5, 2025.

The response to this item is incorporated by reference from the discussion responsive thereto under the captions “Management and Corporate Governance,” “Delinquent Section 16(a) Reports,” if applicable, “Corporate Code of Conduct” and “ Insider Trading Policy and Policy Regarding Hedging and Other Prohibited Transactions ” in our Proxy Statement for the 2026 Annual Meeting of Stockholders expected to be held on June 4, 2026.

EXECUTIVE COMPENSATION

27 unchanged sentences

Lease Agreements

10.1 .1 Lease Agreement, dated October 12, 1995, between the Registrant and Boyer Research Park Associates V, by its general partner, the Boyer Company

(Exhibit 10.2) 11/8/1996 000-26642

.2 Amendment to Phase I Lease Agreement, dated February 3, 2016, between the Registrant and HCPI/UTAH II, LLC

(Exhibit 10.1) 5/4/2016 000-26642

Lease Termination Agreement, dated December 18, 2023, between the Registrant and HCPI/Utah II, LLC

10-K (Exhibit 10.1.3)

2/28/2024 000-26642

10.2 .1 Lease Agreement-Research Park Building Phase II, dated March 6, 1998, between the Registrant and Research Park Associated VI, by its general partner, the Boyer Company, L.C.

(Exhibit 10.44) 9/24/1998 000-26642

.2 Amendment to Phase II Lease Agreement, dated February 3, 2016, between Myriad Genetics, Inc.

and HCPI/UTAH II, LLC

(Exhibit 10.2) 5/4/2016 000-26642

Lease Termination Agreement, dated December 18, 2023, between Myriad Genetics, Inc.

and HCPI/Utah II, LLC

10-K (Exhibit 10.2.3)

2/28/2024 000-26642

10.3 .1 Lease Agreement, dated March 31, 2001, between the Registrant and Boyer Research Park Associates VI, by its general partner, The Boyer Company, L.C.

(Exhibit 10.1) 5/15/2001 000-26642

.2 Amendment to Phase III Lease Agreement, dated February 3, 2016, between Myriad Genetics, Inc.

and HCPI/UTAH II, LLC

(Exhibit 10.3) 5/4/2016 000-26642

Number Exhibit Description Filed with this

Report Incorporated by

Reference herein

Schedule Filing Date SEC File/

Lease Termination Agreement, dated December 18, 2023, between Myriad Genetics, Inc.

and HCPI/Utah II, LLC

10-K (Exhibit 10.3.3)

2/28/2024 000-26642

Lease Agreemen t, dated February 9, 2022, between Myriad G enetics, Inc.

Lease Agreement, dated February 9, 2022, between Myriad Genetics, Inc.

and Bay Bridge/Corporate, LLC

1 unchanged sentence

2/28/2024 000-26642

Amendment to Building D Lease Agreement, dated April 10, 2024, between Myriad Genetics, Inc.

.2 Second Amendment to Building D Lease Agreement, dated April 10, 2024, between Myriad Genetics, Inc.

and ATP SLC D, LLC

10-K (Exhibit 10.4.2)

2/28/2025 000-26642

Lease, effective December 7, 2021, between Myriad Women's Health, Inc.

2 unchanged sentences

2/28/2024 000-26642

L ease Agreement, dated December 1, 2012, by and between Assurex Health, Inc.

Lease Agreement, dated December 1, 2012, by and between Assurex Health, Inc.

and the City of Mason, Ohio

F ifth Addendum to Lease Agreement, dated February 20 , 2025, between As surex Health, Inc.

10-K (Exhibit 10.6.1)

2/28/2025 000-26642

Fifth Addendum to Lease Agreement, dated February 20, 2025, between Assurex Health, Inc.

and the City of Mason, Ohio

10-K (Exhibit 10.6.2)

2/28/2025 000-26642

Agreements with Executive Officers and Directors

Non-Employee Director Compensation Policy (effective June 2025)+

10-Q (Exhibit 10.4)

8/6/2025 000-26642

Form of D irector and E xecutive O fficer I ndemnification A greement+

Form of Director and Executive Officer Indemnification Agreement+

(Exhibit 10.34) 8/25/2009 000-26642

1 unchanged sentence

8-K (Exhibit 10.1) 10/15/2020 000-26642

Executive Employment Agreement between the Registrant and Paul J.

Diaz dated July 24, 2020+

10.1) 11/9/2020 000-26642

Performance-Based Restricted Stock Unit Agreement between Registrant and Paul J.

Diaz dated October 8, 2020+

10.2) 11/9/2020 000-26642

Restricted Stock Unit Agreement between the Registrant and Paul J.

Diaz dated August 13, 2020+

10.3) 11/9/2020 000-26642

Performance-Based Non-Qualified Stock Option Agreement between the Registrant and Paul J.

1 unchanged sentence

10.4) 11/9/2020 000-26642

Number Exhibit Description Filed with this

Report Incorporated by

Reference herein

Schedule Filing Date SEC File/

Non-Qualified Stock Option Agreement between the Registrant and Paul J.

1 unchanged sentence

10.5) 11/9/2020 000-26642

Form of Separation and Release Agreement between the Registrant and Paul J.

Consulting Agreement, dated February 24, 2025, by and between the Company and Paul J.

(Exhibit 10.5)

2/24/2025 000-26642

E x e c u t i v e Employment Agreement, dated October 1 7 , 202 3 , between Myriad Genetics, Inc.

Executive Employment Agreement, dated October 17, 2023, between Myriad Genetics, Inc.

and Samraat S.

1 unchanged sentence

11/7/2023 000-26642

Number Exhibit Description Filed with this

Report Incorporated by

Reference herein

Schedule Filing Date SEC File/

Chief Operating Officer Severance and Change of Control Agreement, dated December 11, 2023, by and between Myriad Genetics, Inc.

2 unchanged sentences

2/28/2024 000-26642

Executive Employment Agreement, dated December 15, 2023, between Myriad Genetics, Inc.

and Scott Leffler+

10-K (Exhibit 10.17)

2/28/2024 000-26642

Amended and Restated Employment Agreement, dated February 24, 2025, between Myriad Genetics, Inc.

12 unchanged sentences

2/24/2025 000-26642

Consulting Agreement, dated February 24, 2025, by and between the Company and Paul J.

Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly +

10-Q (Exhibit 10.9)

5/7/2025 000-26642

Performance-Based Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly +

10-Q (Exhibit 10.10)

5/7/2025 000-26642

Separation Agreement and Release of Claims, dated October 1, 2025, by and between the Company and Scott J.

(Exhibit 10.1)

10/7/2025 000-26642

Executive Employment Agreement, dated Au gust 14, 2025, by and between the Company and Benjamin R.

10-Q (Exhibit 10.4)

11/4/2025 000-26642

Equity Compensation Plans

2 unchanged sentences

6/5/2025 000-26642

Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan+

(Exhibit 10.11) 8/13/2020 000-26642

Amended and Restated 2012 Employee Stock Purchase Plan +

Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan (Director) +

(Exhibit 10.11) 8/13/2020 000-26642

2 unchanged sentences

5/4/2023 000-26642

Credit Agreement

Credit Agreement dated June 30, 2023, among Myriad Genetics, Inc., the other loan parties from time to time party thereto, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent and issuing bank

8-K (Exhibit 10.1)

7/6/2023 000-26642

Pledge and Security Agreement dated June 30, 2023, among Myriad Genetics, Inc., each of the other Guarantors and JPMorgan Chase Bank, N.A., as administrative agent for the secured parties

8-K (Exhibit 10.2)

7/6/2023 000-26642

Amended and Restated 2012 Employee Stock Purchase Plan+

(Exhibit 10.1) 6/2/2022 000-26642

Number Exhibit Description Filed with this

2 unchanged sentences

Schedule Filing Date SEC File/

First Amendment to Credit Agreement and Pledge and Security Agreement, dated as of October 31, 2023, among Myriad Genetics, Inc., the other loan parties party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent

Credit Agreement

Credit Agreement, dated July 31, 2025, a mong Myriad Genetics, Inc.

, the lenders from time to time party thereto, and Orbimed Royalty and Credit Opportunities IV, LP, as initial lender and administrative agent

8-K (Exhibit 10.1)

7/31/2025 000-26642

Ple dge and Security Agreement, dated July 31, 2025, among My riad Genetics, Inc., each of the other Guarantors and Orbimed Royalty and Credit Opportunities IV, LP, as administrative agent for the secured parties

8-K (Exhibit 10.2)

7/31/2025 000-26642

First Amendment to Credit Agreement , dated January 5, 2026, among Myr iad Genetics Inc., the lenders party thereto, and Orbimed Royalty and Credit Opportunities IV, LP, as a dministrative agent

Other Exhibits

19 I nsider Trading Policy

19 Insider Trading Policy

10-K (Exhibit 19)

2/28/2025 000-26642

21.1 List of Subsidiaries of the Registrant

14 unchanged sentences

MYRIAD GENETICS, INC.

/s/ Samraat S.

President and Chief Executive Officer

2 unchanged sentences

President, Chief Executive Officer and Director (Principal Executive Officer)

Diaz February 28, 2025

Chief Financial Officer (Principal Financial Officer)

/s/ Samraat S.

February 24, 2026

Chief Accounting Officer (Principal Accounting Officer)

/s/ Natalie Munk February 28, 2025

Chief Financial Officer (Principal Financial and Accounting Officer)

/s/ Benjamin R.

February 24, 2026

Louise Phanstiel Chair of the Board February 24, 2026

13 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 9A. Controls and Procedures